Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Sep 18, 2021 4:32pm
177 Views
Post# 33883592

RE:RE:RE:RE:RE:RE:RE:For anyone new here

RE:RE:RE:RE:RE:RE:RE:For anyone new here
Too much dilution kills a stock and upward sp movement is almost always negatively affected. Aristotle has been unleased after multiple years in the making and it is now time for quarterly revenue to stand on its own and generate enough to pay operating costs - remember we also have a sizeable amount of cash on hand as well. This is the basis for any successful company and Stage needs to be included in that group. The flip side of continual high interest loans or ongoing dilution just won't work in the long run.



RelevantStock wrote:
capebretongirl wrote: We simply cannot absorb any more dillution


CBG, what do you mean by that? Because I am pretty sur there will be dillution at some point down the road, before a year for sure.


<< Previous
Bullboard Posts
Next >>